Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesDividends payablesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Envoy Medical (COCH) Accounts Payables (2022 - 2025)

Historic Accounts Payables for Envoy Medical (COCH) over the last 4 years, with Q3 2025 value amounting to $2.7 million.

  • Envoy Medical's Accounts Payables rose 5258.96% to $2.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.7 million, marking a year-over-year increase of 5258.96%. This contributed to the annual value of $1.7 million for FY2024, which is 630.63% up from last year.
  • Envoy Medical's Accounts Payables amounted to $2.7 million in Q3 2025, which was up 5258.96% from $1.6 million recorded in Q2 2025.
  • Envoy Medical's 5-year Accounts Payables high stood at $3.4 million for Q3 2023, and its period low was $658899.0 during Q1 2022.
  • Over the past 4 years, Envoy Medical's median Accounts Payables value was $1.6 million (recorded in 2023), while the average stood at $1.6 million.
  • In the last 5 years, Envoy Medical's Accounts Payables surged by 21558.64% in 2023 and then plummeted by 4803.31% in 2024.
  • Envoy Medical's Accounts Payables (Quarter) stood at $1.0 million in 2022, then soared by 54.94% to $1.6 million in 2023, then grew by 6.31% to $1.7 million in 2024, then soared by 62.29% to $2.7 million in 2025.
  • Its Accounts Payables stands at $2.7 million for Q3 2025, versus $1.6 million for Q2 2025 and $1.7 million for Q1 2025.